Pilot Study of Thrombophilic States in Newly Diagnosed Patients With High-Grade Gliomas
- Determine the overall hazard rate of first venous thromboembolism per person-year of
follow-up in patients undergoing antineoplastic therapy for newly diagnosed high-grade
- Correlate ABO blood type with incidence of venous thromboembolism in these patients.
- Correlate factor VIII level with incidence of venous thromboembolism in these patients.
- Determine the overall and individual incidence rate of thromboembolism in these
- Correlate clinical variables, such as type of antineoplastic treatments, Karnofsky
performance status, and type of tumor, with incidence of venous thromboembolism in
- Correlate demographic factors, such as age, with incidence of venous thromboembolism in
OUTLINE: This is a pilot, multicenter study.
Patients undergo blood collection for blood typing (if not already obtained) and factor VIII
and C-reactive protein levels at baseline. Patients are followed to obtain information on
their Karnofsky performance status, treatment they receive for their brain tumor, and
occurrence of any thrombotic events (e.g., pulmonary embolism or deep-vein thrombosis).
Patients are followed every 28 days until the development of thrombotic events, after which
they are followed every 2 months for survival.
PROJECTED ACCRUAL: A total of 107 patients will be accrued for this study.
Observational Model: Case Control, Time Perspective: Prospective
Thrombosis-free survival as assessed by objectively documented deep vein thrombosis or pulmonary embolism
until dvt or death
Michael B. Streiff, MD
Sidney Kimmel Comprehensive Cancer Center
United States: Federal Government
|Abramson Cancer Center of the University of Pennsylvania||Philadelphia, Pennsylvania 19104-4283|
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||Baltimore, Maryland 21231-2410|
|Cleveland Clinic Taussig Cancer Center||Cleveland, Ohio 44195|
|Josephine Ford Cancer Center at Henry Ford Hospital||Detroit, Michigan 48202|
|Winship Cancer Institute of Emory University||Atlanta, Georgia 30322|
|Wake Forest University Comprehensive Cancer Center||Winston-Salem, North Carolina 27157-1096|
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|
|H. Lee Moffitt Cancer Center and Research Institute at University of South Florida||Tampa, Florida 33612|
|Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham||Birmingham, Alabama 35294|